December 2018 Vol 9, No 12
The PD-L1 inhibitor durvalumab showed an overall survival benefit in patients with unresectable stage III non–small cell lung cancer (NSCLC) in the phase 3 PACIFIC trial.
Immunotherapy is one of the hottest concepts in oncology care. Also called biologic therapy, this type of cancer treatment boosts the body’s own natural defenses to fight cancers.
Results 1 - 8 of 8